Shield Therapeutics reported positive results from a further study of a treatment for iron deficiency in adults with inflammatory bowel disease.
The open-label extension phase of the study of Feraccru was a pivotal phase III randomized, placebo-controlled, double-blind trial in chronic kidney disease patients with inflammatory bowel disease.
Shield said it demonstrated superiority of Feraccru when a change in haemoglobin from baseline after 16 weeks of treatment was compared to placebo.
This was followed by a 36-week open-label extension phase, during which all subjects were treated with Feraccru.
For those patients initially treated with Feraccru, Hb levels were maintained over the 36-week follow-up period and the treatment continued to be well tolerated.
In addition, subjects who switched to Feraccru for an open-label phase showed a similar mean rise in Hb over their first 16 weeks of treatment.
'Such positive long-term treatment data for Feraccru in complex patients with chronic diseases like CKD provides a very promising signal for the future commercial success of Feraccru,' chief executive and founder Carl Sterritt said.
'Having previously seen similar positive long-term effects in IBD patients with IDA this further clinical trial data provides additional evidence that Feraccru is well-tolerated by a majority of treated patients and is effective at correcting IDA.'
'We hope that this positive data provides the necessary evidence to both prescribers and patients with iron deficiency with or without anaemia that Feraccru offers a simple to administer, well tolerated and efficacious treatment alternative that does not require hospital-based administration.'
At 8:07am: (LON:STX) Shield Therapeutics Plc share price was +3.1p at 45.5p